Medical Condition News

RSS

Mayo Clinic and collaborators to test new ways to provide specialized TBI care

For people who are hospitalized for traumatic brain injury, recovery may involve physical and cognitive problems that linger for years. The road back to health can be even more arduous for those who live in remote rural areas and don't have access to brain rehabilitation specialists. Mayo Clinic and collaborators, have received a $2.2 million federal grant to test new ways to provide specialized TBI care, with a focus on reaching rural areas and underserved urban populations.

7 Nov 2012

Low vitamin D levels mediate racial disparities in pain

A new study reveals that black Americans display lower levels of vitamin D and greater pain sensitivity compared to white Americans. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), indicate that vitamin D deficiency may be one of many factors that account for increased pain in older black Americans with knee osteoarthritis (OA).

7 Nov 2012

Scientists identify group of small molecules that interfere with polyphosphate activity

Scientists have identified a group of small molecules that interfere with the activity of a compound that initiates multiple steps in blood clotting, including those that lead to the obstruction of veins or arteries, a condition called thrombosis. Blocking the activity of this compound, polyphosphate, could treat thrombosis with fewer bleeding side effects than the drugs that are currently on the market.

7 Nov 2012

UCLA study to uncover risk profiles of breast cancer survivors likely to suffer from depression

UCLA researchers received a five-year, $5 million grant from the National Cancer Institute that will fund a study seeking to uncover risk profiles of breast cancer survivors likely to suffer from depression.

7 Nov 2012

LipoScience presents key findings related to LDL-P and CVD at AHA annual meeting

LipoScience, Inc., an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today presented key findings related to lipoprotein particles (LDL-P) and cardiovascular disease at the Annual Meeting of the American Heart Association (AHA) in Los Angeles.

7 Nov 2012

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.

7 Nov 2012

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used medication to treat high cholesterol, due to their bodies' inability to tolerate or sufficiently respond to the medicine.

7 Nov 2012

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.

7 Nov 2012

Turning off GSK-3α protein activity can prevent heart remodeling

When a person has a heart attack, portions of the heart muscle die in the next several days or even weeks if deprived of oxygen for long enough. The recovering heart slowly remodels itself, even fostering the growth of new blood vessels, in an attempt to regain some of its former function. But all too often, the remodeling is actually harmful, and the damaged heart is on an inevitable downward slide to heart failure.

6 Nov 2012

Researchers show how bacteria control processes in human cells

Bacteria can talk to each other via molecules they themselves produce. The phenomenon is called quorum sensing, and is important when an infection propagates. Now, researchers at Link-ping University in Sweden are showing how bacteria control processes in human cells the same way.

6 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.

6 Nov 2012

Geldanamycin degrades VEGFR2 protein that triggers blood vessel growth

The drug, geldanamycin, is well known for attacking a protein associated with the spread of breast cancer. However, a laboratory-based study found it also degraded a different protein that triggers blood vessel growth.

6 Nov 2012

$Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina$

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Cryopraxis/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Comprehensive overview of vascular risk factors to Alzheimer's disease

Over the last 15 years, researchers have found a significant association between vascular diseases such as hypertension, atherosclerosis, diabetes type 2, hyperlipidemia, and heart disease and an increased risk of Alzheimer's disease.

6 Nov 2012

Seniors can play an important role in reducing risks associated with prescription medications

Common medication to treat insomnia, anxiety, itching or allergies can have a negative impact on memory or concentration in the elderly, according to Dr. Cara Tannenbaum, Research Chair at the Institut universitaire de g-riatrie de Montr-al (IUGM, Montreal Geriatric University Institute) and Associate Professor of Medicine and Pharmacy at the University of Montreal (UdeM).

6 Nov 2012

Paragonix files PMNA with FDA for Sherpa Pak Cardiac Transport System

Paragonix Technologies, Inc. today announced that it has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its Paragonix Sherpa Pak Cardiac Transport System (CTS).

6 Nov 2012

Biologists determine how blind mole rats fight off cancer

Biologists at the University of Rochester have determined how blind mole rats fight off cancer-and the mechanism differs from what they discovered three years ago in another long-lived and cancer-resistant mole rat species, the naked mole rat.

6 Nov 2012

Racial differences in fatal coronary heart disease associated with risk factor burden

Despite treatment advances for coronary heart disease over the past 20 years, black men and women still have twice the risk of fatal coronary heart disease compared with white men and women, according to a study from the University of Alabama at Birmingham appearing in the Nov. 7, 2012 issue of the Journal of the American Medical Association.

6 Nov 2012

Medical Condition News

Mayo Clinic and collaborators to test new ways to provide specialized TBI care

Low vitamin D levels mediate racial disparities in pain

Scientists identify group of small molecules that interfere with polyphosphate activity

UCLA study to uncover risk profiles of breast cancer survivors likely to suffer from depression

LipoScience presents key findings related to LDL-P and CVD at AHA annual meeting

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

AMG 145 can reduce LDL cholesterol levels by up to 66% after 12 weeks

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

Turning off GSK-3α protein activity can prevent heart remodeling

Researchers show how bacteria control processes in human cells

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

Geldanamycin degrades VEGFR2 protein that triggers blood vessel growth

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Comprehensive overview of vascular risk factors to Alzheimer's disease

Seniors can play an important role in reducing risks associated with prescription medications

Paragonix files PMNA with FDA for Sherpa Pak Cardiac Transport System

Biologists determine how blind mole rats fight off cancer

Racial differences in fatal coronary heart disease associated with risk factor burden

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Latest News